Agios Pharmaceuticals | AGIO - Loan Capital


Agios Pharmaceuticals reported $1.06M in Loan Capital for its fiscal quarter ending in September of 2022.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Astellas Pharma JPY 320B 0 Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
Bayer EUR 30.68B 1.15B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Merck USD 46.67B 77M Mar/2026
Moderna USD 603M 7M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novartis USD 37.45B 7.86B Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025